William Blair Investment Management LLC Raises Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

William Blair Investment Management LLC increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 380,324 shares of the medical equipment provider's stock after purchasing an additional 9,245 shares during the period. William Blair Investment Management LLC owned approximately 0.55% of Lantheus worth $34,024,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of LNTH. Wilmington Savings Fund Society FSB bought a new position in Lantheus during the third quarter valued at approximately $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus in the fourth quarter worth approximately $27,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the last quarter. World Investment Advisors LLC bought a new position in shares of Lantheus in the third quarter worth approximately $60,000. Finally, Parkside Financial Bank & Trust grew its holdings in shares of Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after purchasing an additional 280 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price on the stock. B. Riley lowered their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday. Truist Financial raised their price objective on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, JMP Securities reissued a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Remove Ads

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by corporate insiders.

Lantheus Stock Performance

Shares of LNTH traded down $1.14 during trading hours on Friday, hitting $97.71. The company had a trading volume of 1,069,481 shares, compared to its average volume of 936,576. The firm has a fifty day moving average price of $92.67 and a 200-day moving average price of $96.64. The stock has a market capitalization of $6.69 billion, a price-to-earnings ratio of 16.26 and a beta of 0.38. Lantheus Holdings, Inc. has a 52-week low of $57.92 and a 52-week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.